bims-tuinly Biomed News
on Tumor-infiltrating lymphocytes therapy
Issue of 2026–09–20
thirty papers selected by
Pierpaolo Ginefra, Ludwig Institute for Cancer Research



  1. Cell Rep Med. 2026 Sep 15. pii: S2666-3791(26)00468-4. [Epub ahead of print] 103051
      Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) induces durable responses in metastatic melanoma, yet the clonal and transcriptional dynamics governing tumor-reactive T cell fate during ex vivo expansion and after transfer remain poorly understood. Here, we perform longitudinal single-cell RNA and T cell receptor sequencing across five time points, from baseline tumors through two-phase ex vivo expansion to post-infusion blood and tumor biopsies, in seven melanoma patients, resolving both the CD8+ and CD4+ compartments. Tumor-reactive CD8+ T cells are reinvigorated from exhaustion and acquire HLA-II-high or KLF2-high profiles. We further dissect the tumor-responsive CD4+ compartment in depth, revealing lineage-dependent reinvigoration in which follicular helper T cells adopt an effector state while exhausted CD4+ T cells retain dysfunction. In non-responders, across three cohorts, co-transferred type 17 T cells and de novo regulatory T cell expansion after transfer associate with treatment failure. These data define subtype-specific signatures across both lineages to guide TIL expansion.
    Keywords:  T cell exhaustion; T cell receptor repertoire; adoptive cell therapy; cancer immunotherapy; follicular helper T cells; melanoma; regulatory T cells; tumor-infiltrating lymphocytes; tumor-reactive T cells; type 17 T cells
    DOI:  https://doi.org/10.1016/j.xcrm.2026.103051
  2. Int J Mol Sci. 2026 Aug 27. pii: 7664. [Epub ahead of print]27(17):
      The efficacy of adoptive cell transfer (ACT) therapy in solid tumors is often limited by the functional exhaustion and insufficient persistence of infused CD8+ T cells within the tumor microenvironment. Through the integrated analysis of single-cell transcriptomic data, this study identified enolase 1 (ENO1), a key rate-limiting enzyme in glycolysis, as a core gene highly correlated with the superior anti-tumor phenotype of tumor-infiltrating lymphocytes (TILs). However, in vitro functional validation demonstrated that the overexpression of Eno1 failed to substantially enhance the anti-tumor efficacy of mouse T cells, suggesting the presence of a downstream metabolic regulatory node within the glycolytic cascade that restricts the conversion of carbon flux. To overcome this limitation, we introduced the small molecule activator TEPP-46 to target a crucial downstream metabolic hub, pyruvate kinase M2 (PKM2). Transcriptome sequencing confirmed that PKM2 activation successfully induced systemic metabolic rewiring in CD8+ T cells and broadly upregulated the expression of cytotoxicity- and memory-related genes. In an in vivo B16-OVA melanoma model, OT-1 T cells subjected to In vitro TEPP-46 pretreatment exhibited significantly enhanced tumor-suppressive capabilities and effectively promoted the preferential differentiation of T cells into central memory T cells (Tcm). In summary, this study highlights the importance of targeting downstream metabolic nodes to bypass intrinsic metabolic restrictions in T cells. It demonstrates that in vitro metabolic pretreatment via PKM2 activation represents an effective translational strategy for optimizing the anti-tumor efficacy of ACT cell products.
    Keywords:  CD8+ T cells; adoptive cell transfer; enolase 1; glycolysis; metabolic reprogramming
    DOI:  https://doi.org/10.3390/ijms27177664
  3. J Clin Med. 2026 Sep 05. pii: 6888. [Epub ahead of print]15(17):
      Background/Objectives: Lymphocyte activation gene-3 (LAG-3) is an inhibitory immune checkpoint molecule that may contribute to immune escape in diffuse large B-cell lymphoma (DLBCL). This study aimed to characterize LAG-3 expression in neoplastic cells and tumor-infiltrating lymphocytes (TILs) and to investigate its associations with clinicopathological features and clinical outcome. Methods: This retrospective, single-center study included 210 patients with DLBCL diagnosed between 2007 and 2019. LAG-3 expression was evaluated immunohistochemically in whole-tissue sections. Tumor-cell expression was assessed according to the percentage and intensity of positive cells, while LAG-3-positive TILs were quantified as the mean number of positive lymphocytes per high-power field (HPF). Associations with clinicopathological parameters, treatment response, overall survival, and progression-free survival (PFS) were analyzed. Results: LAG-3 staining of varying intensity was observed in neoplastic cells in 177 cases (84.3%), and 82 cases (39.0%) were classified as LAG-3 positive using a 10% tumor-cell cut-off. The median number of LAG-3-positive TILs was 5/HPF. Male patients showed a higher percentage of LAG-3-positive tumor cells than female patients (p = 0.039). Moderate-to-strong tumor-cell staining was significantly more frequent in cases with >5 LAG-3-positive TILs/HPF than in those with ≤5 TILs/HPF (p = 0.018). LAG-3 expression parameters were not significantly associated with treatment response or overall survival. Univariate Cox regression analysis also showed no significant association between overall survival and LAG-3-positive TIL count, tumor-cell LAG-3 percentage, or staining intensity. Exploratory PFS analysis in 66 evaluable patients also showed no significant association with LAG-3 expression parameters. Conclusions: LAG-3 expression in DLBCL occurs in both neoplastic cells and TILs. The association between increased LAG-3-positive TILs and stronger tumor-cell expression supports further investigation of LAG-3 across both cellular compartments. No significant association with overall survival was observed in this cohort; however, the limited number of survival events precludes definitive conclusions regarding its prognostic significance. Further studies using standardized assessment methods and larger, clinically well-characterized cohorts are warranted.
    Keywords:  DLBCL; LAG-3; diffuse large B-cell lymphoma; immune checkpoint; immunohistochemistry; tumor microenvironment; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.3390/jcm15176888
  4. Cancer Manag Res. 2026 ;18 629872
       Background: Treatment of colorectal cancer includes surgery and chemotherapy, along with advances in personalised therapies, which focus on achieving safer and more effective outcomes. One of the processes underlying colorectal cancer is microsatellite instability (MSI), and CD8+ Tumor Infiltrating Lymphocytes (TILs) belong to the immune cell subset that shows high impact on cancerous cells. The purpose of this study is to determine whether MSI, CD8+ TILs expression, and chemotherapy response are related.
    Methods: This is a retrospective cohort study of colorectal cancer patients who received chemotherapy in the neoadjuvant setting, prior to tumor resection, at a tertiary general hospital in West Java, Indonesia. The MSI examination was carried out using qPCR-HRM (BioColoMelt-Dx), and the TILs CD8+ expression was carried out using immunohistochemistry. The chemotherapy response was evaluated using response evaluation criteria for solid tumors (RECIST).
    Results: Forty-one subjects were enrolled in this study. There were three subjects (7.3%) with microsatellite instability (1 MSI-L, 2 MSI-H) and 19 subjects (46.3%) with high CD8+ TILs expression. There were 28 (68.3%) subjects in stage III, followed by stage IV (22%) and stage II (9.8%). There were 10 subjects (24%) who showed progressive disease, and 16 subjects (39%) with high expression of CD8+ TILs showed partial chemotherapy response. MSI showed a significant association with age (P<0.05). The CD8+ TILs expression showed no significant association with sex, subtype, grade, or tumor location, but significantly associated with age, stage and chemotherapy response (P < 0.05). Subjects with MSI tend to have early onset disease. Colorectal cancer with high CD8+ TILs expression was less likely to have metastasis (stage IV) and had a better chemotherapy response when compared to those with low CD8+ TILs expression.
    Conclusion: The MSI status showed no significant relationship with CD8+ TILs. Patients with high CD8+ TILs showing a relationship with a better chemotherapy response and a better prognosis in colorectal cancer patients.
    Keywords:  MSI; chemotherapy; colorectal cancer; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.2147/CMAR.S629872
  5. Clin Breast Cancer. 2026 Aug 22. pii: S1526-8209(26)00151-5. [Epub ahead of print]26(10): 52-57
       BACKGROUND: Neoadjuvant systemic therapy (NST) is the standard of care for high-risk early triple-negative breast cancer (TNBC). Although pathological complete response (pCR) is strongly associated with improved survival, reliable and accessible predictors of response remain limited. The aim of this study was to evaluate whether peripheral blood immune markers and tumor-infiltrating lymphocytes (TILs) can predict pCR in patients with TNBC treated with neoadjuvant pembrolizumab plus chemotherapy.
    MATERIALS AND METHODS: In this single-institution retrospective study, 60 patients with stage II-III TNBC received NST according to the KEYNOTE-522 regimen followed by curative surgery. Pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and TIL levels were assessed. Associations with pCR were analyzed using logistic regression models.
    RESULTS: Thirty-six patients (60.0%) achieved pCR. In the univariate analysis, low NLR, high TILs, and histological type were significantly associated with pCR, whereas PLR was not. Multivariate analysis identified low NLR and histological type as independent predictors of pCR. Patients with both low NLR and high TILs demonstrated the highest pCR rate.
    CONCLUSION: NLR may be a simple and accessible predictor of pCR in patients with TNBC receiving neoadjuvant pembrolizumab plus chemotherapy. Combining peripheral blood immune markers with intratumoral immune parameters may enhance treatment stratification.
    Keywords:  Immune checkpoint inhibitors; Neoadjuvant systemic therapy; Peripheral blood immune markers; Tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.1016/j.clbc.2026.08.013
  6. Front Immunol. 2026 ;17 1917770
      Lung cancer remains the leading cause of cancer-related mortality worldwide, and despite the transformative impact of immune checkpoint inhibitors (ICIs), primary and acquired resistance, limited efficacy in immune-cold tumors such as extensive-stage small cell lung cancer (ES-SCLC), and the absence of durable responses in a substantial proportion of patients define the unmet need that T cell-redirected therapies aim to address. These strategies engage, engineer, and deliver cytotoxic T cells against tumor cells independently of preexisting immunity, and this review provides a comprehensive overview of the four major modalities under clinical development in lung cancer: bispecific T cell engagers (BiTEs), tumor-infiltrating lymphocyte (TIL) therapy, chimeric antigen receptor T cell (CAR-T) therapy, and T cell receptor-engineered T cell (TCR-T) therapy. Among these, tarlatamab, a DLL3×CD3 BiTE, has achieved the most advanced clinical validation, receiving traditional FDA approval in November 2025 for second-line ES-SCLC following Phase 3 DeLLphi-304 data demonstrating superior overall survival versus chemotherapy (median 13.6 vs. 8.3 months; HR 0.60). TIL therapy is the leading adoptive cell approach in non-small cell lung cancer (NSCLC), with lifileucel demonstrating a 25.6% ORR in anti-PD-1-resistant disease and a 64.3% ORR when combined with pembrolizumab in ICI-naïve patients, though manufacturing complexity and cost constrain broad access. CAR-T and TCR-T therapies remain in early proof-of-concept phases, limited by the absence of uniformly expressed tumor-restricted surface antigens in NSCLC, MHC class I downregulation, and the sub-1% eligibility rates imposed by HLA restriction in TCR-T programs, while generating important engineering insights around genome editing, armored cytokine payloads, and neoantigen targeting strategies. Shared challenges across all modalities include antigen loss under therapeutic pressure, T cell exhaustion driven by the immunosuppressive lung tumor microenvironment, and the absence of prospectively validated predictive biomarkers for patient selection. Combination strategies pairing T cell-redirected therapies with ICIs, antibody-drug conjugates, and allogeneic or innate immune effectors represent the most promising path toward durable benefit. As the field advances toward Phase 3 trials, biomarker-selected patient populations, and scalable allogeneic manufacturing platforms, T cell-redirected therapy is positioned to extend the survival frontier for patients whose lung cancer has escaped existing treatments.
    Keywords:  T-cell redirected therapy; TCR-engineered T cells; bispecific T cell engager; chimeric antigen receptor T (CAR T) therapy; lung cancer; tumor-infiltrating lymphocyte
    DOI:  https://doi.org/10.3389/fimmu.2026.1917770
  7. Curr Opin Oncol. 2026 Sep 18.
       PURPOSE OF REVIEW: Despite maximal neoadjuvant chemoimmunotherapy, nearly 40% of early-stage triple-negative breast cancer (TNBC) patients fail to achieve pathological complete response, underscoring an urgent need for biomarkers capable of guiding treatment modulation. This review summarizes recent advances in tumor-infiltrating lymphocytes (TILs), circulating tumor DNA (ctDNA), and genomic signatures, exploring their potential integration into clinical decision-making.
    RECENT FINDINGS: TILs remain the most validated, cost-effective prognostic biomarker, although standardized scoring is still needed to overcome interobserver variability. ctDNA has emerged as a dynamic, real-time prognostic tool, with postneoadjuvant detection strongly predicting relapse and worse outcomes. Nonetheless, optimal sampling timing remains undefined. Genomic signatures, particularly TNBC-DX, provide standardized, reproducible prognostic information by integrating immune and proliferative gene expression. Emerging data suggest that combining these biomarkers may offer a complementary and synergistic effect.
    SUMMARY: Multibiomarker integration, supported by prospective validation and automated models, represents a promising approach to personalize treatment algorithms in early-stage TNBC, balancing efficacy and toxicity while guiding escalation and de-escalation strategies.
    Keywords:  artificial intelligence; circulating tumor DNA; clinical utility; triple-negative breast cancer; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.1097/CCO.0000000000001266
  8. Cancer. 2026 Sep 15. 132(18): e70612
      The year 2025 marked significant advances in autologous cellular therapy for melanoma and solid tumors, building on landmark regulatory approvals in 2024. Lifileucel, the first Food and Drug Administration-approved tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, demonstrated durable efficacy in the 5-year analysis of the C-144-01 trial, with an objective response rate (ORR) of 31.4% and prolonged responses in a heavily pretreated population. Real world data further supported its effectiveness, with higher ORR likely reflecting earlier lines of therapy and differences in patient selection. Preferentially expressed antigen in melanoma (PRAME)-targeted T-cell receptor (TCR) T-cell therapy (anzu-cel, IMA203) showed promising activity in a phase 1 study, with ORR of approximately 50% in checkpoint inhibitor refractory melanoma, durable responses, and manageable toxicity, validating PRAME as a high value target across multiple tumor types. Next-generation engineered TIL approaches emerged to address limitations of high-dose IL-2. OBX-115, an IL-2 independent TIL platform expressing membrane-bound IL-15 regulated by acetazolamide, demonstrated early clinical activity with ORR of 67% in initial phase 1 data. Additional strategies, including CRISPR-mediated gene editing and checkpoint disruption, highlight a shift toward programmable, self-sustaining cellular therapies. Personalized neoantigen-based therapies advanced with early clinical validation of adoptive T-cell platforms and mRNA vaccines, demonstrating immune activation and improved recurrence-free survival in melanoma. Finally, afamitresgene autoleucel (afami-cel), a MAGE-A4 directed TCR-T therapy, showed durable efficacy in synovial sarcoma and expanding activity across solid tumors, establishing proof of concept for TCR-T approaches. Collectively, these advances position autologous cellular therapy as an evolving standard of care in melanoma and a promising modality across solid tumors, with ongoing efforts focused on improving accessibility, overcoming resistance, and optimizing combinatorial strategies.
    Keywords:  cellular therapy; melanoma; solid tumor
    DOI:  https://doi.org/10.1002/cncr.70612
  9. Int J Mol Sci. 2026 Aug 28. pii: 7716. [Epub ahead of print]27(17):
      Interleukin-12 (IL-12) potently promotes the recruitment and activation of immune cells within the tumor microenvironment (TME), highlighting its immense potential for cancer therapy. However, its dose-limiting systemic toxicity and short half-life severely hinder its clinical translation. Here, we design a tumor-conditionally activated IL-12 prodrug termed αHSA-proIL-12. This engineered molecule integrates a cleavable albumin-binding nanobody (αHSA) domain to extend the half-life and enhance tumor targeting alongside a masking domain that occludes the IL-12 receptor-binding site to prevent nonspecific activation. This construct undergoes selective cleavage by matrix metalloproteinases (MMPs) that are highly expressed in the TME to release highly penetrant, free, low-molecular-weight IL-12 locally. This tumor-restricted activation process directly facilitates the selective recruitment and activation of tumor-infiltrating lymphocytes (TILs). The intravenous administration of an extremely low dose of 108 pmol per dose of αHSA-proIL-12 completely cleared MC38 tumors without inducing systemic toxicity. The maximum tolerated dose of this molecule exceeded 2 nmol, yielding a remarkably wide therapeutic index >18.5. Mechanistically, αHSA-proIL-12 effectively reprogrammed the immunosuppressive TME by expanding the numbers of effector CD8+ T cells and natural killer cells while upregulating IFN-γ expression and significantly reducing the proportion of regulatory T cells. This immunological remodeling has the potential to convert "cold" tumors into "hot" tumors. Notably, this treatment achieved complete regression and durable immunity in a subset of mice with multiple refractory immune-cold tumors, including Panc02 pancreatic cancer, 4T1 triple-negative breast cancer, and B16F10 melanoma, when administered as a monotherapy or in combination with PD-L1 blockade. Furthermore, when combined with surgery, αHSA-proIL-12 effectively prevented the postoperative recurrence and distant metastasis of advanced 4T1 tumors. This modular platform provides a clinically promising strategy to overcome the toxicity bottleneck of cytokines and substantially advances the development of combination cancer immunotherapies.
    Keywords:  cytokine; half-life; immune checkpoint blockade (ICB); immunotherapy; interleukin-12; prodrug; surgery
    DOI:  https://doi.org/10.3390/ijms27177716
  10. Front Immunol. 2026 ;17 1899098
      Triple-negative breast cancer (TNBC) is an immunogenic but clinically heterogeneous breast cancer subtype. Stromal tumor-infiltrating lymphocytes (TILs), PD-L1 expression, and tumor mutational burden provide useful but incomplete summaries of the tumor immune microenvironment. Spatial immune biomarkers retain tissue architecture and ask where immune cells are located, which cells they contact, and whether local neighborhoods are inflamed, excluded, suppressive, or organized into tertiary lymphoid structures (TLS). In this critical review, we examine CD8+ T-cell proximity, stromal versus intratumoral localization, suppressive myeloid and regulatory T-cell (Treg)-rich niches, TLS maturity, and spatial checkpoint co-expression in TNBC. We also compare multiplex immunofluorescence, multiplexed ion beam imaging by time-of-flight (MIBI-TOF), imaging mass cytometry, spatial transcriptomics, and hematoxylin-and-eosin (H&E)-based artificial intelligence in terms of spatial resolution, molecular depth, formalin-fixed, paraffin-embedded (FFPE) compatibility, scalability, reproducibility, and clinical feasibility. Most reported associations with prognosis or treatment response remain retrospective or exploratory, and their definitions are sensitive to sampling, segmentation, and threshold selection. The most clinically interpretable candidates are compartment-aware TIL measures, CD8+ T-cell-tumor proximity, and TLS-related features, but none is ready to guide treatment independently. Progress will require locked biomarker definitions, multisite analytical validation, external cohorts, and prospective trials with pre-specified spatial endpoints.
    Keywords:  digital pathology; immune niches; immunotherapy; spatial biomarkers; tertiary lymphoid structures; triple-negative breast cancer; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.3389/fimmu.2026.1899098
  11. Cancer Res Commun. 2026 Sep 18.
      Ampullary adenocarcinoma is rare and its immune biomarker landscape is incompletely characterized. This paper evaluated mismatch repair (MMR), programmed death-ligand 1 (PD-L1) and compartment-specific CD3/CD8 tumor-infiltrating lymphocytes (TILs) in resected tumors and explored associations with disease-specific survival (DSS). Ninety-nine patients underwent pancreaticoduodenectomy at Vancouver General Hospital between 1984-2013. Duplicate 0.6-mm tissue microarrays were assessed for MMR proteins, PD-L1 combined positive score (CPS), and stromal and intra-epithelial CD3 and CD8 counts. DSS was estimated by Kaplan-Meier methods. Exploratory Cox models adjusted for age, histologic subtype, pT group, pN status, and adjuvant chemotherapy. There were 44 DSS events. MMR deficiency was present in 37/99 tumors (37.4%). PD-L1 was evaluable in 87 tumors; 57/87 (65.5%) had CPS ≥1 and 24/87 (27.6%) had CPS ≥10. Intraepithelial CD8+ T-cells were present in 23/98 tumors (23.5%). PD-L1 CPS ≥1, PD-L1 CPS ≥10 and MMR status were not associated with DSS by log-rank testing (P=0.35, P=0.98, and P=0.74 respectively). In the pT-adjusted model, intraepithelial CD8 presence was associated with lower disease-specific hazard (HR 0.422; 95% CI 0.144-0.994; likelihood-ratio P=0.048), although the Wald sensitivity test was not significant (P=0.074). Continuous log-transformed intraepithelial CD8 counts showed a concordant, method-dependent signal. dMMR and PD-L1 expression were common in this historical resected cohort. Intraepithelial CD8 infiltration was associated with DSS, but the borderline and inferential-method-dependent estimates require external validation. These prognostic data do not establish benefit from immune checkpoint blockade.
    DOI:  https://doi.org/10.1158/2767-9764.CRC-26-0302
  12. World J Oncol. 2026 Oct;17(5): 751-764
       Background: Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have transformed lung cancer therapy, but their efficacy is often limited in tumors with low programmed cell death ligand 1 (PD-L1) expression and immunologically "cold" tumor microenvironments. This study aimed to evaluate the safety and therapeutic efficacy of combining a RAD001-adjuvanted influenza vaccine with PD-1 blockade and to explore its immunological mechanisms in a murine lung cancer model.
    Methods: C57BL/6 mice bearing Lewis lung carcinoma (LLC) tumors, characterized by low PD-L1 levels (10.28%), were randomized to receive control, anti-PD-1 monotherapy, or anti-PD-1 combined with either a split influenza vaccine, an MF59-adjuvanted vaccine, or a RAD001-adjuvanted vaccine. Primary endpoints included tumor growth kinetics and survival. Safety was assessed via histopathological analysis of major organs and biochemical analyses. Mechanistic changes were evaluated through immunophenotyping of tumor-infiltrating lymphocytes (TILs) and serum cytokine profiling.
    Results: The RAD001-adjuvanted vaccine synergized with anti-PD-1 therapy, resulting in superior tumor growth inhibition compared to all other groups. This synergy was associated with a remodeled tumor microenvironment, showing increased CD8+ T-cell infiltration and a higher CD8+/regulatory T-cell ratio. Serum analysis revealed a shift toward a Th1-dominant cytokine profile (a trend toward increased interferon-gamma and interleukin-2). Histopathological and biochemical examination confirmed no treatment-related toxicities in the heart, liver, lungs, kidneys, or spleen.
    Conclusions: RAD001-adjuvanted influenza vaccination safely enhances the efficacy of anti-PD-1 therapy in PD-L1-low murine lung cancer by promoting a pro-inflammatory immune microenvironment. These findings suggest that strategic vaccine adjuvant selection can broaden the therapeutic reach of immune checkpoint inhibitors.
    Keywords:  Cancer immunotherapy; Influenza vaccine; Lung cancer; PD-L1–low; Rad001 adjuvant; Tumor microenvironment
    DOI:  https://doi.org/10.14740/wjon2831
  13. Sci Bull (Beijing). 2026 Sep 04. pii: S2095-9273(26)01015-7. [Epub ahead of print]
      Adoptive cell transfer (ACT) has achieved durable clinical responses in hematological malignancies, yet remains limited in solid tumors owing to poor T cell infiltration, inadequate persistence, and tumor-driven immunosuppression. Here, we report a bio-orthogonally engineered probiotic-T cell chimera (T-FOLactis) that creates a mutually reinforcing cellular-microbial system, in which FOLactis, an engineered Lactococcus lactis expressing a Flt3L-OX40L fusion protein, provides localized immunostimulatory cues to enhance T cell activation and effector function, while adoptively transferred T cells serve as cytotoxic effectors and mobile carriers that facilitate delivery of the bacterial payload to the tumor microenvironment. Using strain-promoted azide-alkyne cycloaddition chemistry, FOLactis bacteria were covalently anchored onto the surface of T cells, generating a cell-bound platform for spatially restricted immune modulation. In syngeneic colorectal cancer models, T-FOLactis reduced tumor burden by 78.1% compared with saline-treated controls and by 65.0% relative to conventional ACT, while prolonging median survival from 22 to 46 d without overt systemic toxicity. Mechanistically, T-FOLactis promoted dendritic cell (DC)-T cell proximity and established a spatially organized immune-licensing niche that amplified the functional impact of FOLactis-induced inflammatory cues, including IL-18. This spatial configuration was associated with enhanced coupling of cytokine availability, DC maturation, local co-stimulation and cytotoxic CD8+ T cell effector programming. IL-18 blockade impaired this licensing program and reduced therapeutic benefit, supporting IL-18 as a key functional mediator within the DC-T cell licensing niche. Together, these findings establish a modular cell-surface engineering strategy for augmenting ACT in colorectal cancer through coordinated immune network engagement.
    Keywords:  Adoptive cell therapy; Bio-orthogonal click chemistry; Cell-surface engineering; Engineered probiotics; Tumor microenvironment remodeling
    DOI:  https://doi.org/10.1016/j.scib.2026.09.009
  14. Mol Cancer. 2026 Sep 07. pii: 216. [Epub ahead of print]25(1):
      Treatment with adoptively transferred T cells is challenged by limited longevity of therapeutic cells within tumors. To enhance the durability of anti-tumor T cell products, we have created T cell receptors (TCRs) with built-in co-stimulatory molecules. We observed that TCRs coupled to ICOS mediated exceptionally long-term responses, including delay of tumor recurrence and cures in a mouse melanoma model. TCR:ICOS T cells showed enhanced and antigen-specific production of inflammatory cytokines, enrichment for a stem-like state and resistance to exhaustion. TCR:ICOS-mediated activation of PI3K and NFκB, yet restrained activation of AKT. Genetic ablation of the ICOS-PI3K pathway neutralized the long-term anti-tumor effects. To translate TCR:ICOS to human T cells, we identified a single amino acid change in the cytosolic tail which enabled functional surface expression without proneness to TCR mispairing nor competition for CD3. Notably, the optimized receptor sustained functional performance of human T cells upon repeated stimulation across multiple tumor antigens. Collectively, we present a novel and uniformly applicable TCR:ICOS format that supports fitter T cell products for adoptive cell therapy.
    Keywords:  Adoptive T cell therapy; Co-stimulatory TCR; Differentiation of T cells; Exhaustion of T cells; Gene engineering; Inflammation; Solid tumors
    DOI:  https://doi.org/10.1186/s12943-026-02765-9
  15. Med Oncol. 2026 Sep 15. pii: 285. [Epub ahead of print]43(10):
       PURPOSE: PD-1 and LAG-3 are frequently used as markers of T cell exhaustion, yet the prognostic relevance and phenotypic characteristics of PD-1+LAG-3+CD8+ T cells in gastric cancer (GC) remain poorly defined. This study aimed to investigate their association with clinical outcomes and characterize their immune characteristics across independent GC cohorts.
    METHODS: Four independent GC cohorts were analyzed: the Zhongshan Hospital cohort (ZSGC, n = 298), The Cancer Genome Atlas cohort (TCGA, n = 371), an Immune Checkpoint Blockade cohort (ICB, n = 45), and the Yonsei cohort (n = 433). Intratumoral PD-1+LAG-3+CD8+ T cell infiltration was quantified by immunofluorescence staining and transcriptomic gene signature scoring. Survival analysis was performed using Kaplan-Meier estimation and multivariate Cox regression. Functional characterization was performed by flow cytometry on resected GC tissue. The immune microenvironment composition was evaluated using computational analyses.
    RESULTS: PD-1+LAG-3+CD8+ T cells were enriched within tumors compared to adjacent normal mucosa, and their infiltration correlated with advanced tumor stage, poor differentiation, microsatellite instability, and Epstein-Barr virus (EBV)-positive molecular subtypes. High intratumoral infiltration was significantly associated with improved overall survival in both the ZSGC and TCGA cohorts, whereas single-positive PD-1+CD8+ or LAG-3+CD8+ T cells showed no such association. In the ICB cohort, higher infiltration was associated with a higher response rate to pembrolizumab. Intratumoral PD-1+LAG-3+CD8+ T cells exhibit an activated phenotype characterized by increased expression of CD137, IFN-γ, perforin, and CXCL13, along with elevated TCF7 and lower PD-1 levels, suggesting a tumor-reactive, pre-exhausted state. High infiltration was further associated with an immune-active tumor microenvironment.
    CONCLUSIONS: High intratumoral infiltration of PD-1+LAG-3+CD8+ T cells is associated with favorable prognosis and an immune-active microenvironment in GC. These cells display phenotypic features consistent with a pre-exhausted state and may serve as independent prognostic biomarkers and candidate predictive biomarkers for immunotherapy stratification.
    Keywords:  Gastric cancer; LAG-3; PD-1; Prognosis; Tumor microenvironment
    DOI:  https://doi.org/10.1007/s12032-026-03384-6
  16. J Genet Eng Biotechnol. 2026 Sep;pii: S1687-157X(26)00121-6. [Epub ahead of print]24(3): 100777
       BACKGROUND: Terminal exhaustion of CD8+ tumour-infiltrating lymphocytes constrains the benefit of immune-checkpoint blockade in hepatocellular carcinoma (HCC). The orphan nuclear receptor NR4A2 (Nurr1) belongs to a transcription-factor family implicated in murine T-cell exhaustion, yet its behaviour in the human HCC microenvironment has not been characterised across data modalities. We asked whether NR4A2 is specifically coupled to the terminal-exhaustion programme of human HCC CD8+ T cells, and whether that coupling is reflected in chromatin, tissue topography and bulk-tumour outcome data.
    METHODS: We reanalysed publicly available human HCC datasets spanning four modalities: single-cell RNA sequencing (scRNA-seq; GSE149614, GSE98638, GSE151530, GSE125449), single-cell ATAC sequencing (scATAC-seq; GSE227265), imaging-based spatial transcriptomics (10× Xenium human liver-cancer section) and bulk RNA sequencing with overall-survival annotation (TCGA-LIHC). NR4A2 was profiled across cell compartments and, at higher resolution, across CD8+ T-cell states defined from curated exhaustion, progenitor, effector and naïve gene modules. We tested NR4A2-exhaustion coupling at single-cell and pseudobulk level, examined NR4A2 motif accessibility, traced NR4A2 along a diffusion-pseudotime exhaustion axis, evaluated spatial co-localisation of exhausted CD8+ T cells with tumour-associated macrophages (TAMs), benchmarked machine-learning classifiers of the exhausted state, and compared the human NR4A2 co-expression direction with the published NR4A1/2-knockout phenotype. We additionally trained interpretable gradient-boosted-tree models with SHAP attribution to characterise the exhausted and NR4A2-high states, scored a NR4A2 co-expression regulon, related the programme to immunotherapy-relevant signatures, and modelled overall survival using a CD8-infiltration-adjusted exhaustion score.
    RESULTS: NR4A2 was broadly expressed across HCC compartments and was highest in myeloid cells rather than being T-cell restricted; at whole-compartment and bulk-tumour resolution it was not a clean exhaustion marker. At the resolution of CD8+ T-cell states, however, NR4A2 was sharply enriched in terminally exhausted cells (mean 3.62 versus 1.05; Mann-Whitney p ≈ 3.4 × 10-83) and correlated with the exhaustion module (single-cell Spearman ρ = 0.45) but not with the effector module (ρ = 0.06), arguing that NR4A2 is not a generic activation gene. NR4A2 expression increased monotonically along a diffusion-pseudotime axis toward terminal exhaustion (ρ = 0.37). In Xenium tissue, exhausted CD8+ T cells were modestly but significantly enriched in the neighbourhood of TAMs relative to other CD8+ T cells (permutation p = 0.005). The human NR4A2 co-expression direction was 83% concordant with the published NR4A1/2-knockout differential-expression direction. In bulk TCGA-LIHC, NR4A2 was lower in tumour than adjacent liver and only weakly exhaustion-correlated, consistent with hepatocyte-dominated bulk signal and reinforcing the need for compartment-resolved analysis. Interpretable machine learning attributed NR4A2-high status to an immediate-early/AP-1 activation programme, a NR4A2 co-expression regulon was selectively active in exhausted cells, and the programme tracked the T-cell-inflamed phenotype (ρ = 0.87); although raw bulk NR4A2 was non-prognostic, a CD8-infiltration-adjusted exhaustion score independently predicted shorter overall survival (hazard ratio 1.42 per standard deviation, p < 0.001).
    CONCLUSIONS: A NR4A2 co-expression regulon was most active in exhausted cells; explainable modelling linked NR4A2-high status to an immediate-early/AP-1 activation programme; the programme marked immune-hot tumours; and although bulk NR4A2 was non-prognostic, a CD8-infiltration-adjusted exhaustion score was independently associated with worse overall survival (HR 1.42 per SD, p < 0.001). Across four independent data modalities, NR4A2 behaves as a resolution-dependent marker of the terminal-exhaustion programme in HCC CD8+ T cells that is spatially associated with the myeloid niche. The convergence supports NR4A2 as a candidate component of an HCC exhaustion signature and a hypothesis-generating target for functional study, while underscoring that its association is masked in bulk and whole-compartment data.
    Keywords:  CD8(+) T-cell exhaustion; Explainable machine learning (SHAP); Hepatocellular carcinoma; Immune checkpoint blockade; NR4A2; Prognostic signature; Single-cell RNA sequencing; Spatial transcriptomics; Tumour microenvironment
    DOI:  https://doi.org/10.1016/j.jgeb.2026.100777
  17. Arch Toxicol. 2026 Sep 15.
      Human leukocyte antigen (HLA) alleles are among the strongest genetic risk factors for idiosyncratic drug toxicity. HLA-A*31:01 is a risk factor for carbamazepine (CBZ)-induced delayed drug hypersensitivity, yet allele carriage alone is insufficient for disease development. CD8+ T cells are implicated in these reactions; however, their activation mechanism remains unclear. Using HLA-A*31:01 knock-in (A31-KI) mice, we investigated whether CBZ exposure elicited CD8+ T-cell responses in vivo. The mice received CBZ for 7 days by oral administration (300 mg/kg/day) and auricular application (25 mg/kg/day). CBZ alone did not induce clear CD8+ T-cell activation. Under CD4+ T-cell depletion, CBZ markedly increased programmed cell death protein 1 (PD-1) expression in CD44highCD62Llow CD8+ T cells, suggesting PD-1-mediated restraint of CBZ-responsive activation. Subsequent PD-1 blockade enhanced CD8+ T-cell activation in auricular lymph nodes and induced skin inflammation with elevated serum thymus and activation-regulated chemokine; both were attenuated by CD8+ T-cell depletion. To clarify how CBZ activated CD8+ T cells, we performed ex vivo analyses using splenocytes. CBZ (50 µM) induced proliferation of CD44highCD8+ T cells, whereas this response was absent in purified CD8+ T-cell cultures and reduced by HLA class I and costimulatory blockade, supporting an antigen-presenting cell-dependent mechanism. Collectively, CBZ can activate CD8+ T cells; however, this response is restrained and remains latent. When immune control is disrupted, particularly in an HLA-A*31:01-bearing host, the response can progress to a CD8+ T cell-dependent inflammatory phenotype. Thus, A31-KI mice provide an in vivo platform for understanding CBZ-associated idiosyncratic toxicity and pathogenesis.
    Keywords:  CD8+ T cells; Carbamazepine; Drug hypersensitivity; HLA-A*31:01; Idiosyncratic drug toxicity; Immune regulation
    DOI:  https://doi.org/10.1007/s00204-026-04536-3
  18. Sci Adv. 2026 Sep 18. 12(38): eaee8251
      Naïve T cells maintain quiescence yet must respond rapidly to antigens, but how they prime this capacity is unclear. We identify histone variant H2A.Z as a key regulator of an epigenetic training program that licenses quiescent naïve CD8+ T cells for future activation. H2A.Z deficiency disrupts naïve T cell homeostasis and effector responses. Multiomics reveals that H2A.Z is selectively deposited at oxidative phosphorylation (OXPHOS) gene promoters in quiescent naïve CD8+ T cells, priming the chromatin for rapid transcriptional induction. This training is developmentally instructed by tonic interleukin-7 (IL-7) signaling and regulated by transcription factor GABPα. Age-related decline in IL-7 signaling reduces H2A.Z occupancy and impairs T cell activation, while IL-7 supplementation or enforced H2A.Z expression rescues this defect. H2A.Z overexpression also enhances chimeric antigen receptor T cell stemness and antitumor efficacy. Our work defines an IL-7R-GABPα-H2A.Z-OXPHOS axis that epigenetically establishes metabolic and functional fitness in quiescent T cells, offering insights for immunotherapy targeting ageing and tumors.
    DOI:  https://doi.org/10.1126/sciadv.aee8251
  19. J Cancer. 2026 ;17(9): 1576-1582
       Background: Prognostic outcomes vary considerably among patients with metastatic melanoma. We examined the association of the prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) with overall survival in this patient population.
    Methods: We retrospectively evaluated 60 patients with metastatic melanoma treated at a single center. PNI was derived from serum albumin and absolute lymphocyte count. A cut-off of 52 was identified by ROC analysis and used to define the PNI groups. Overall survival was analyzed using the Kaplan-Meier method and Cox proportional hazards regression. PNI was entered into separate multivariable models with NLR or SII.
    Results: Overall survival was longer in patients with PNI ≥52 than in those with PNI <52 (log-rank p = 0.008). PNI, NLR, SII, and immunotherapy use were associated with OS in univariate Cox analysis. After multivariable adjustment, PNI remained significant in the model containing NLR (HR: 0.36, 95% CI: 0.15-0.85; p = 0.020) and in the model containing SII (HR: 0.37, 95% CI: 0.16-0.88; p = 0.024). Immunotherapy use was also independently associated with OS, whereas NLR and SII were not. PNI remained associated with OS when analyzed as a continuous variable (HR: 0.91, 95% CI: 0.84-0.98; p = 0.008). The AUC for PNI was 0.706 (95% CI: 0.551-0.833; p = 0.015).
    Conclusion: Higher PNI was independently associated with longer overall survival in this cohort of patients with metastatic melanoma. These findings support further investigation of PNI as a readily available prognostic marker, although validation in larger independent cohorts is needed.
    Keywords:  metastatic melanoma; neutrophil-to-lymphocyte ratio; prognosis; prognostic nutritional index; survival; systemic immune-inflammation index
    DOI:  https://doi.org/10.7150/jca.136818
  20. Nat Immunol. 2026 Sep 11.
      CD8+ T cell dysfunction is a major obstacle to hepatitis B virus (HBV) clearance and antitumor immunity. Here, using a humanized mouse model, we identify a T cell receptor targeting a clinically relevant HBV epitope and reveal ANKRD11 as a key epigenetic regulator of CD8+ T cell dysfunction in chronic infection and tumors. Ankrd11 knockout in CD8+ T cells enhances HBV-specific T cell proliferation and effector differentiation, especially under immunosuppressive conditions, via AP-1 family gene upregulation. Loss of Ankrd11 both drives the conversion of progenitor exhausted T cells into terminally exhausted T cells, and reprograms PD-1-TOX- tolerant cells into functional effectors, improving antiviral and antitumor responses. Ankrd11-deficient T cells show increased granzyme and superior effector function, enhancing viral control and tumor regression. These findings position ANKRD11 as a promising immunotherapy target for chronic HBV infection and cancer.
    DOI:  https://doi.org/10.1038/s41590-026-02652-x
  21. Biomol Biomed. 2026 Sep 11.
      The comparative prognostic value of preoperative inflammatory markers in resected biliary tract cancer (BTC) remains uncertain. We evaluated the associations of neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) with overall survival (OS), focusing on NLR versus dNLR. This single-center retrospective cohort included 109 patients undergoing curative-intent resection. Exploratory cut-offs were derived using receiver operating characteristic analysis and the Youden index. Survival associations were assessed using Kaplan-Meier analysis and separate multivariable Cox models for NLR and dNLR to address multicollinearity. During follow-up, 70 patients died, and median OS was 19.43 months. Elevated NLR and dNLR were associated with shorter OS in univariable analyses. After adjustment, NLR ≥2.11 remained associated with shorter OS (hazard ratio, 4.043; 95% confidence interval, 1.199-13.635; p = 0.024), whereas dNLR ≥1.75 did not (p = 0.321). Neither marker was statistically significant when modeled continuously in adjusted analyses. PLR and LMR showed no statistically significant univariable associations with OS. Combining NLR, dNLR, and PLR yielded only modest discrimination (area under the curve, 0.666). These findings support further investigation of preoperative NLR as a prognostic marker in resected BTC. However, cohort-derived cut-offs and combined risk stratification remain exploratory and require validation in larger independent cohorts before clinical application.
    DOI:  https://doi.org/10.17305/bb.2026.14636
  22. Nat Commun. 2026 08 17. pii: 9839. [Epub ahead of print]17(1):
      Programmed cell death protein 1 (PD-1) is expressed by T cells during progressive multifocal leukoencephalopathy (PML), a life-threatening brain disease caused by the human-only JC polyomavirus (JCPyV). PD-1 checkpoint immunotherapy has benefited some PML patients, but reasons for its variable outcomes are unclear. Using mouse polyomavirus (MuPyV), we show that PD-1 loss acts in a brain-autonomous manner to increase the magnitude of brain-infiltrating CD4+ and CD8+ T cells and the function of virus-specific CD8+ T cells; in concert, brain virus levels decline and neuroinflammation increases. Deletion of PD-1 in CD4+ T cells, but not CD8+ T cells, recapitulates effects of global PD-1 loss. Single-cell RNA sequencing shows that PD-1-deficient CD8+ T cells cluster as effectors while transcripts associated with proliferation and function are upregulated with loss of PD-1. Thus, CD4+ T cell-intrinsic PD-1 signaling balances antiviral defense against neural injury during polyomavirus infection of the brain.
    DOI:  https://doi.org/10.1038/s41467-026-76762-3
  23. J Transl Med. 2026 Aug 21. pii: 1187. [Epub ahead of print]24(1):
       BACKGROUND: Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in hematologic malignancies, but its efficacy against solid tumors is severely limited by two core barriers: the scarcity of uniformly expressed tumor-associated antigens (TAAs) and the immunosuppressive tumor microenvironment (TME), in which PD-1/PD-L1 signaling promotes irreversible T cell exhaustion. This study aimed to develop a novel T cell receptor-mimic (TCRm) CAR-T platform with autocrine anti-PD-1 nanobody secretion to simultaneously overcome antigen heterogeneity and TME immunosuppression.
    METHODS: A lentiviral vector encoding a TCRm CAR targeting HLA-A*02:01-restricted WT1 and a secreted anti-PD-1 nanobody was constructed to generate WT1-CAR-Nb T cells. WT1-CAR T cells (CAR-only control) and Mock T cells were also prepared. In vitro assays included antigen-specific cytotoxicity, proinflammatory cytokine (IFN-γ, TNF-α) detection, chronic antigen stimulation-induced T cell exhaustion model, and transcriptomic analysis. In vivo efficacy was evaluated in human ovarian cancer SKOV3-A2 xenograft mice via tumor growth monitoring, survival analysis, intratumoral T cell infiltration assessment, and safety evaluation.
    RESULTS: WT1-CAR-Nb T cells targeting the HLA-A*02:01-restricted WT1 and constitutively secreting anti-PD-1 nanobody were successfully generated. In vitro functional assays demonstrated that WT1-CAR-Nb T cells exhibited significantly enhanced antigen-specific cytotoxicity and secreted markedly higher levels of proinflammatory cytokines IFN-γ and TNF-α compared with conventional WT1-CAR T cells upon specific antigen stimulation. Critically, autocrine PD-1 nanobody blockade effectively alleviated TME immunosuppression, as reflected by downregulated expression of multiple exhaustion markers (TIM-3, CTLA-4, TIGIT) and preserved proliferative potential under chronic antigen stimulation. In the SKOV3-A2 solid tumor xenograft model, WT1-CAR-Nb T cells mediated superior tumor growth control and significantly prolonged overall survival, which was closely correlated with enhanced intratumoral T cell infiltration and persistent in vivo expansion of engineered T cells.
    CONCLUSION: Local autocrine PD-1 checkpoint blockade potently enhances the effector function and durability of TCRm CAR-T cells. This armored TCRm CAR-T strategy is a promising therapeutic approach for solid tumor immunotherapy, with broad translational potential for other TCRm CAR systems targeting distinct peptide-MHC epitopes.
    Keywords:  Chimeric antigen receptor T cells; PD‑1 nanobody; Solid tumor immunotherapy; Tumor microenvironment
    DOI:  https://doi.org/10.1186/s12967-026-08765-z
  24. Cancer Res. 2026 Sep 15.
      The aged tumor microenvironment can impair antitumor T cell function, but the molecular regulators that become limiting in this setting remain poorly defined. In a recent issue of Cell, Chen and colleagues harness in vivo CRISPR screening to compare the effects of genetic perturbations in tumor-reactive CD8+ T cells across young and aged hosts. The screen reveals that increased T cell persistence or an effector-like transcriptional state does not necessarily translate into improved tumor control and identifies Dusp5 and Zfp219 as distinct functional regulators. DUSP5 broadly restrains ERK-dependent proliferation, and its loss improves tumor control in both young and aged mice. ZFP219, by contrast, preferentially limits cytotoxicity in aged hosts; its deletion increases granzyme expression and improves tumor control specifically in the aged setting. Human tumor datasets show that ZNF219 expression in intratumoral CD8+ T cells increases with age and is associated with poorer clinical outcomes. Moreover, Zfp219 loss enhances the response to PD-1 blockade in aged mice, producing complete tumor clearance in a subset of animals and durable protection after rechallenge. Together, these findings show that host age can reshape the functional consequences of T cell perturbations and reveal age-dependent genetic vulnerabilities with potential therapeutic relevance.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-26-3854
  25. PLoS One. 2026 ;21(9): e0351697
       BACKGROUND: Adoptive T cell therapy is a promising alternative to conventional therapies for certain solid tumours. Personalized tumour-trained lymphocytes (pTTL) is an autologous T cell therapy derived from tumour-draining regional lymph nodes (RLNs), trained to target patient-specific neoantigens arising from tumour-specific mutations. The protocol for an ongoing phase I/IIa first-in-human trial of pTTL in Stage IV Colorectal Cancer (CRC), NEOGAP-CRC-01, is presented here.
    METHODS: pTTL is produced by in vitro expansion of T cells from RLNs using EpiTCer® technology. Tumour-specific neoantigen-forming mutations are identified through next-generation sequencing of tumour and blood samples and the most optimal neoantigens are selected using the bioinformatics software PIOR®. Selected neoantigen epitopes are included in recombinantly produced proteins and attached to paramagnetic EpiTCer® micro-particles, forming the tumour-selective T cell stimulus TC0301 used in pTTL manufacturing. The trial comprises three parts: Part I includes sequencing of tumour and blood samples, RLNs collection, TC0301 production and pTTL manufacturing. Part II includes preconditioning, pTTL administration and 26 weeks follow-up, and Part III consists of up to five years follow-up after pTTL administration. Up to 16 patients can be included. pTTL is administered as a single-dose infusion following preconditioning with cyclophosphamide and fludarabine. Between the limits of 20 x 106-1 x 109 cells, the entire pTTL yield will be administered.
    DISCUSSION: pTTL represents a novel approach within adoptive T-cell therapy, using autologous T cells trained to target selected neoantigens without genetic modification. The integration of PIOR® and EpiTCer® technology enables individualized neoantigen identification and delivery. Interpretation of treatment efficacy may be challenging due to the highly personalized nature of pTTL and the heterogeneity of CRC. The primary trial endpoint is safety. Secondary endpoints include objective treatment response, overall survival, and progression-free survival. Biomarkers of pTTL persistence, product characteristics, and treatment response will be assessed.
    TRIAL REGISTRATION: Authorized under the Clinical Trial Regulation (Regulation EU No 536/2014), EU CT #2024-512296-13-00. ClinicalTrials.gov ID NCT05908643.
    DOI:  https://doi.org/10.1371/journal.pone.0351697
  26. Front Immunol. 2026 ;17 1922207
      Most prior studies on immune-related fatty liver disease have focused on changes in immune cell quantity and composition. However, this "cell-count model" does not fully explain the regional onset of fibrosis, spatial heterogeneity of lesions, or variable immunotherapy responses. Immune dysregulation in metabolic dysfunction-associated steatotic liver disease (MASLD) involves not only compositional changes but also spatial redistribution and functional alterations of immune cells within specific hepatic lobule regions. Emerging multi-omics and spatial transcriptomic data suggest that chemokine gradient remodeling, metabolic microenvironment reprogramming, and circadian rhythm disruption may drive immune cell relocation along the portal-central axis. We propose that immune dysregulation in MASLD reflects a disruption of spatial immune homeostasis and introduce the liver lobule as the basic unit for spatial immune analysis. The lobule comprises three functionally distinct zones: the periportal zone (zone 1), which serves as the primary immune surveillance barrier; the pericentral zone (zone 3), characterized by metabolic stress and functional impairment; and the fibrotic septum, which in advanced disease creates a structurally confined immunosuppressive niche. To quantify regional T cell dysfunction, we propose a Regional Exhaustion Index (REI) as a conceptual framework, calculated as the ratio of PD-1+TIM-3+ CD8+ T cells to total CD8+ T cells within a defined microanatomical region. This metric translates regional immune conditions into a quantifiable measure of T cell functional impairment across different lobular zones. We outline how chemokine remodeling, metabolic reprogramming, and circadian disruption drive spatially distinct immune alterations: reduced immune surveillance in zone 1, functional impairment in zone 3, and structural confinement in the fibrotic septum. We also discuss the translational potential of this framework for biomarker discovery, patient stratification, and targeted therapy. The REI remains an exploratory metric requiring validation of its biological meaning and clinical utility. Current evidence is largely correlational, and the causal role of spatial immune changes in disease progression demands further investigation. Nonetheless, this spatial perspective complements existing paradigms and may guide the development of spatially targeted therapeutic strategies.
    Keywords:  immune exhaustion; liver lobule partitioning; macrophage heterogeneity; metabolic dysfunction-associated steatotic liver disease; regional exhaustion index; spatial immunology
    DOI:  https://doi.org/10.3389/fimmu.2026.1922207
  27. Hemasphere. 2026 Sep;10(9): e70476
      Chronic lymphocytic leukemia (CLL) exhibits marked clinical heterogeneity that cannot be fully explained by genetic alterations, underscoring the critical role of the tumor microenvironment in disease progression and therapeutic resistance. To delineate the temporal evolution of immune dysregulation in CLL, we used the Eµ-TCL1 adoptive transfer (TCL1-AT) mouse model combined with high-dimensional spectral flow cytometry to longitudinally profile lymphoid and myeloid compartments. To assess the reproducibility across different disease kinetics, we analyzed seven independent TCL1-AT cohorts generated from distinct primary tumors. CLL progression was associated with coordinated restructuring of adaptive and innate immune cell populations. Within the T-cell compartment, early activation and effector expansion transitioned to a progressive accumulation of terminally exhausted CD8+ T cells. Concurrently, immunoregulatory populations expanded, including regulatory type 1 (Tr1)-like CD4+ T cells, activated regulatory T cells (Tregs) and, importantly, a previously underappreciated Eomes-expressing Treg subset. Natural killer (NK) cells exhibited transient expansion followed by differentiation and acquisition of exhaustion markers. Myeloid cell profiling revealed an expansion of immunosuppressive PD-L1high patrolling monocytes, mature regulatory dendritic cells (mregDCs), and phenotypic reprogramming of dendritic cells (DCs) consistent with impaired antigen presentation and promotion of T-cell exhaustion and regulatory T-cell subsets. Despite substantial variation in leukemia kinetics, expansion of patrolling monocytes, exhausted CD8+ T cells, and Tregs was consistently observed across all seven independent TCL1-AT cohorts, demonstrating robust immune remodeling. Collectively, our findings demonstrate a stepwise transition toward a suppressive microenvironment involving innate and adaptive immune compartments in the Eµ-TCL1 mouse model, providing a framework for understanding immune failure in CLL and informing strategies to restore anti-leukemic immunity.
    DOI:  https://doi.org/10.1002/hem3.70476
  28. Gan To Kagaku Ryoho. 2026 Sep;53(9): 545-549
      Recent advances in cancer immunology have revealed that tumor progression is profoundly influenced by interactions between tumor cells and the host immune system. Although the immune system can recognize and eliminate malignant cells through immune surveillance, tumors can evade immune-mediated destruction by acquiring various immune escape mechanisms. Regulatory T cells (Tregs) represent one of the key immunosuppressive components that facilitate tumor immune evasion. Tregs, typically characterized as CD4+CD25+FoxP3+ T cells, play an essential role in maintaining immune tolerance and preventing excessive immune responses under physiological conditions. However, within the tumor microenvironment (TME), Tregs suppress antitumor immunity through multiple mechanisms, including inhibition of effector T-cell activation, modulation of antigen-presenting cells, secretion of immunosuppressive cytokines, and metabolic regulation. Accumulation of Tregs in tumor tissues has been associated with poor clinical outcomes in various solid tumors. Renal cell carcinoma (RCC) is known as an immunogenic tumor characterized by abundant immune-cell infiltration. Despite the presence of numerous tumor-infiltrating lymphocytes, effective antitumor immunity is often impaired in RCC, partly due to immunosuppressive networks within the TME. In particular, Tregs contribute to the establishment of an immunosuppressive environment that limits the activity of cytotoxic T cells and reduces the efficacy of immune checkpoint inhibitors (ICIs), which have become a cornerstone of therapy for advanced RCC. In this review, we summarize the biological characteristics and immunosuppressive mechanisms of Tregs and discuss their roles in shaping the immune landscape of RCC. Furthermore, we highlight emerging therapeutic strategies targeting Tregs, including depletion, functional inhibition, and blockade of Treg recruitment. A deeper understanding of Treg-mediated immune regulation may facilitate the development of more effective immunotherapeutic approaches for RCC and other malignancies.
  29. Cell Rep Med. 2026 Sep 16. pii: S2666-3791(26)00469-6. [Epub ahead of print] 103052
      Multi-drug resistance (MDR) is an almost inevitable endpoint of cancer therapy, driving rapid tumor progression, yet its evolutionary logic remains unclear because MDR tumors are rarely resected. Using paired therapy-naive and MDR melanoma specimens from a clinical trial, integrated with single-cell and spatial multi-omics and evaluated together with datasets from 10 additional cancer types, we identify a recurrent MDR-associated spatial nexus along the tumor-stroma interface. This niche juxtaposes CXCL14+ inflammatory cancer-associated fibroblasts (iCAFs), TREM2+ tumor-associated macrophages (TAMs), and AXL+ dedifferentiated tumor cells, and is accompanied by loss of tumor-reactive CXCL13+CD8+ T cells. In vitro, CXCL14 promotes macrophage migration and TREM2 induction, while TREM2+ TAMs suppress CXCL13+CD8+ T cells via CD86-CTLA4 signaling. TREM2+ TAMs also promote tumor dedifferentiation through oleic acid-driven GAS6-AXL activation. We develop an FAP/TREM2-targeting bispecific antibody to disrupt this spatial nexus and restore therapeutic sensitivity in MDR patient-derived xenograft models with favorable safety.
    Keywords:  bispecific antibody; cancer-associated fibroblasts; dedifferentiation; immunotherapy; melanoma; multi-drug resistance; single-cell sequencing; spatial transcriptomics; targeted therapy; tumor-associated macrophages
    DOI:  https://doi.org/10.1016/j.xcrm.2026.103052
  30. Tumori. 2026 Sep 14. 3008916261457067
       BACKGROUND: Composite scores such as Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), EPSILoN, Pan Immune-Inflammation Value (PIV) and Systemic Immune-Inflammation Index (SII) have shown prognostic value in solid tumors, but evidence in extensive-stage small-cell lung cancer (ES-SCLC) are limited.
    METHODS: This monocentric retrospective/prospective observational study included 67 ES-SCLC patients treated with first-line chemo-immunotherapy. Baseline clinical and laboratory data were collected. LIPI, mGPS, and EPSILoN were calculated according to previously reported methodology; optimal cut-offs for SII and PIV were determined using maximally selected rank statistics. Survival outcomes were estimated through Kaplan-Meier method. Prognostic associations were evaluated through univariate and multivariate Cox proportional hazards models.
    RESULTS: Median progression free survival (PFS) and overall survival (OS) in the study cohort were 4.8 and 11.3 months; 14.9% achieved long term survival (OS 24 months). Poor-risk categories of LIPI (PFS p<0.0001, OS p<0.0001), EPSILoN (PFS p=0.0012, OS p=0.0301), PIV (PFS p=0.0147, OS p=0.00543), and SII (PFS p=0.00016, OS p<0.0001) were strongly associated with inferior outcomes. In multivariate analysis, LIPI, EPSILoN and SII independently predicted both PFS and OS, whereas PIV retained significance for OS only. mGPS did not emerge as an independent prognostic marker.
    CONCLUSIONS: LIPI, SII and EPSILoN demonstrated significant prognostic value in ES-SCLC patients receiving first line chemo-immunotherapy, supporting their role in clinical stratification.
    Keywords:  EPSILoN; LIPI; SCLC; SII; chemo-immunotherapy
    DOI:  https://doi.org/10.1177/03008916261457067